Zobrazeno 1 - 10
of 731
pro vyhledávání: '"C Chastang"'
Autor:
N. Bardin, M. Guarella, M. Desjonquere, N. Fabien, M.-C. Chastang, K. Retornaz, Alexandre Belot, A.-L. Jurquet
Publikováno v:
Archives de Pédiatrie. 22:1263-1267
Juvenile dermatomyositis (JDM) is the most common inflammatory myopathy in children. Its diagnosis is usually made on a clinical basis following the criteria of Bohan and Peter (1975). Recently, the presence of myositis-specific autoantibodies (MSAs)
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
M, Guarella, A-L, Jurquet, K, Retornaz, N, Bardin, M-C, Chastang, M, Desjonquere, N, Fabien, A, Belot
Publikováno v:
Archives de pediatrie : organe officiel de la Societe francaise de pediatrie. 22(12)
Juvenile dermatomyositis (JDM) is the most common inflammatory myopathy in children. Its diagnosis is usually made on a clinical basis following the criteria of Bohan and Peter (1975). Recently, the presence of myositis-specific autoantibodies (MSAs)
Autor:
J. Soria, I. Reach, N. Luong, Alain Baumelou, M.C. Mirshahi, M. Chakroun, C. Chastang, D. Desmichels, S. Mirshahi
Publikováno v:
Artificial Organs. 25:591-595
Low molecular weight heparins (LMWHs) are used for prevention of clotting in the dialysis circuit. The aim of this trial was to define the optimal dose of a new LMWH and to test the efficiency of a single dose at the start of the session. Fifteen pat
Autor:
Michel Beaugrand, C. Chastang, Marianne Ziol, Nathalie Ganne-Carrié, F Chapel, Christos Christidis, Jean-Claude Trinchet, Catherine Guettier, F. Imbert-Bismut
Publikováno v:
Gut. 46:277-282
BACKGROUND/AIMS—A study was undertaken of liver biopsy samples from 229 consecutive patients with alcoholic or hepatitis C virus related cirrhosis who were prospectively followed until January 1996 to evaluate the influence of liver iron content on
Autor:
P. Chaumet Riffaud, I. Bartolomei-Portal, Catherine Buffet, Pierre Bedossa, M. Olivi, Yvon Calmus, Sylvie Chevret, Michel Vidaud, V. Daurat, Françoise Degos, C. Chastang, E. Borotto, Joseph Moussalli, J. P. Richardet, Thierry Poynard, François Bailly, Ghassan Riachi, C. Brechot
Publikováno v:
Journal of Viral Hepatitis. 6:381-386
The aim of this work was to assess the effect of a high-dose (10 million units, MU) short-duration (14 weeks) interferon-α2b (IFN-α2b) regimen in relapsers compared with the standard IFN regimen of 3 MU three times weekly (t.i.w.) for 6 months. Fif
Autor:
E. Spindler, Patrice Morel, A. Marcelli, C. Chastang, Michel Janier, Claire Rabian, S. Strazzi
Publikováno v:
Dermatology. 198:362-369
The evolution of serological tests for syphilis (STSs) after therapy in HIV+ patients is a major point of controversy, with possible seroreactivation and illicit seroreversion in these patients. The aim of our study was to evaluate the long-term outc
Autor:
S. De Botton, H. Dombret, M. Sanz, J. San Miguel, D. Caillot, R. Zittoun, M. Gardembas, A. Stamatoulas, E. Condé, A. Guerci, C. Gardin, K. Geiser, D. Cony Makhoul, O. Reman, J. de la Serna, F. Lefrere, C. Chomienne, C. Chastang, L. Degos, P. Fenaux, the European APL Group
Publikováno v:
ResearcherID
All trans-retinoic acid (ATRA) syndrome is a life-threatening complication of uncertain pathogenesis that can occur during the treatment of acute promyelocytic leukemia (APL) by ATRA. Since its initial description, however, no large series of ATRA sy
Publikováno v:
Vox Sanguinis. 74:95-101
Allogeneic haematopoietic stem cell transplantation (HSCT) has been used to treat thousands of patients, adults and children, with life-threatening haemato-logical diseases. The principal limitations of allogeneic bone marrow transplantation are the
Publikováno v:
European Archives of Oto-Rhino-Laryngology. 254:372-375
A multicenter, double-blind, placebo-controlled study was conducted to investigate the efficacy of an immunostimulant, Ribomunyl, in the prevention of recurrences of infectious rhinitis in adults. This trial involved 327 patients (168 Ribomunyl treat